Glioblastoma multiforme (GBM) is a WHO grade IV glioma and the most common malignant,
primary brain tumor with a 5-year survival of 7.2%. Its highly infiltrative nature, genetic …

Abstract Overactive phosphoinositide 3-kinase (PI3K) in cancer and immune dysregulation
has spurred extensive efforts to develop therapeutic PI3K inhibitors. Although progress has …

Diffuse gliomas represent a heterogeneous group of universally lethal brain tumors
characterized by minimally effective genotype-targeted therapies. Recent advances have …

Single-cell RNA sequencing has revealed extensive transcriptional cell state diversity in
cancer, often observed independently of genetic heterogeneity, raising the central question …

Glioblastoma (GBM) is the most common primary malignant brain tumor in adults and has an
exceedingly low median overall survival of only 15 months. Current standard-of-care for …

Mutations play a fundamental role in the development of cancer, and many create targetable
vulnerabilities. There are both public health and basic science benefits from the …

The proto-oncogene ROS1 encodes a receptor tyrosine kinase with an unknown
physiological role in humans. Somatic chromosomal fusions involving ROS1 produce …

Glioblastoma (GBM) is the most aggressive and deadliest of the primary brain tumors,
characterized by malignant growth, invasion into the brain parenchyma, and resistance to …

This review provides a comprehensive landscape of HGF/c-MET (hepatocyte growth factor
(HGF)/mesenchymal–epithelial transition factor (c-MET)) signaling pathway in cancers. First …

Cancer stem cells (CSCs), known also as tumor-initiating cells, are quiescent, pluripotent,
self-renewing neoplastic cells that were first identified in hematologic tumors and soon after …